[Protective effect of the mushroom polysaccharide Schizophyllan against experimental bacterial infections].
D000818:Animals; D000890:Anti-Infective Agents / Q000627:therapeutic use*; D001487:Basidiomycota; D004927:Escherichia coli Infections / Q000517:prevention & control; D006025:Glycosaminoglycans / Q000627:therapeutic use*; D007710:Klebsiella Infections / Q000517:prevention & control; D008297:Male; D051379:Mice; D012157:Mononuclear Phagocyte System / Q000187:drug effects; D010587:Phagocytosis / Q000187:drug effects; D011008:Pneumococcal Infections / Q000517:prevention & control; D011512:Proteus Infections / Q000517:prevention & control; D011552:Pseudomonas Infections / Q000517:prevention & control; D012481:Salmonella Infections, Animal / Q000517:prevention & control; D013203:Staphylococcal Infections / Q000517:prevention & control; D015054:Zymosan / Q000627:therapeutic use
D000890:Anti-Infective Agents; D006025:Glycosaminoglycans; D015054:Zymosan